At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Belzutifan (drug), Nivolumab (drug), Lenvatinib (drug), Cabozantinib (drug)
- How long the study runs
- Study runs about 97 months (dates as stated)
- About the drug or intervention
- Belzutifan — drug: Belzutifan is administered orally at 120 mg once daily (qd) OR 200 mg qd until progressive disease (PD), unacceptable toxicity, withdrawal of consent, death, investigator decision, or study termination. · Nivolumab — drug: Nivolumab is administered intravenously at 480 mg until PD, unacceptable toxicity, withdrawal of consent, death, investigator decision, or study termination. · Lenvatinib — drug: Lenvatinib is administered orally at 20 mg qd until PD, unacceptable toxicity, withdrawal of consent, death, investigator decision, or study termination. · Cabozantinib — drug: Cabozantinib is administered orally at 60 mg qd until PD, unacceptable toxicity, withdrawal of consent, death, investigator decision, or study termination.
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 450
- Started
- 2026-03-23
- Last checked
- 2026-10
Plain English Summary
What is this study?
- • Testing a new treatment for von hippel-lindau disease
- • Phase3 - 450 participants
- • Researchers are looking for new ways to treat advanced solid tumors and von Hippel-Lindau (VHL)-related tumors: * Advanced means the cancer has spread to other parts of the body (metastatic) or cannot be removed with surgery * Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids * VHL-related tumors are tumors caused by VHL disease
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with von hippel-lindau disease
Where?
- • Glasgow - The Beatson West of Scotland Cancer Centre ( Site 2505)
- • London - St Bartholomew's Hospital ( Site 2500)
- • London - ROYAL MARSDEN HOSPITAL (CHELSEA) ( Site 2502)
- • London - Imperial College Healthcare NHS Trust, Charing Cross Hospital ( Site 2504)
- • +1 more UK sites
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
Researchers are looking for new ways to treat advanced solid tumors and von Hippel-Lindau (VHL)-related tumors: * Advanced means the cancer has spread to other parts of the body (metastatic) or cannot be removed with surgery * Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids * VHL-related tumors are tumors caused by VHL disease. VHL disease is passed down from parents to children and people with VHL disease have a higher chance of getting certain types of cancer Researchers want to learn about the long-term effects of a trial medicine called belzutifan. Belzutifan, also called MK-6482, is designed to block a protein that helps tumors grow and survive. This is an extension trial, which means only people who were in certain other belzutifan trials (called parent trials) may be able to join. The goal of this trial is to learn how long people live after they start taking belzutifan.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
What the study is looking for
- ✓The main inclusion criteria include but are not limited to the following:
- ✓Participants with advanced solid tumors or von Hippel-Lindau-related neoplasms who are participating in...
Who cannot take part
- ✗The main exclusion criteria include but are not limited to the following:
- ✗Has an on-going serious adverse event in the parent study, unless no longer hospitalized and considered clinically...
- ✗Is currently on a dose interruption due to an Adverse Event (AE) in the parent study; once treatment has been...
See the full criteria
Where Is This Study? (5 UK sites)
The Beatson West of Scotland Cancer Centre ( Site 2505)
Glasgow G12 0YN, United Kingdom
St Bartholomew's Hospital ( Site 2500)
London EC1A 7BE, United Kingdom
ROYAL MARSDEN HOSPITAL (CHELSEA) ( Site 2502)
London SW3 6JJ, United Kingdom
Imperial College Healthcare NHS Trust, Charing Cross Hospital ( Site 2504)
London W6 8RF, United Kingdom
The Christie NHS Foundation Trust ( Site 2501)
Manchester M20 4BX, United Kingdom
How to Get in Touch
Toll Free Number
Sponsor contactCONTACT